Update on the Acute Management of Cerebral Venous Thrombosis

Autores

  • Miguel A. Vences Servicio de Neurología, Clínica Anglo Americana. Lima, Peru. | Universidad Peruana Cayetano Heredia, Facultad de Medicina Alberto Hurtado. Lima, Peru. https://orcid.org/0000-0002-8538-6242
  • Rodrigo Guerrero Servicio de Neurología, Neurocirugía y Neurorradiología Intervencional, Clínica Santa María. Santiago de Chile, Chile. https://orcid.org/0000-0002-5634-7535
  • Rodrigo Dècima Hospital de Clínicas. Universidad de la República. Montevideo, Uruguay. https://orcid.org/0000-0002-8287-7724
  • Julián A. Rivillas Service de neurologie, Centre hospitalier de L'Université de Montréal. Montreal, Canada. | Université de Montréal. Montreal, Canada. https://orcid.org/0000-0002-1231-9380

DOI:

https://doi.org/10.20453/rmh.v37i3.7562

Palavras-chave:

Intracranial sinus thrombosis, Anticoagulants, Direct-Acting Oral Anticoagulants, Critical Care, interventional radiology

Resumo

Cerebral venous thrombosis (CVT) is a rare but increasingly recognized cause of stroke with highly variable clinical presentations. Early diagnosis relies on CT or MR venography, as symptoms often range from headache to seizures, focal deficits, or coma. Anticoagulation remains the cornerstone of therapy, even in patients with intracranial hemorrhage. Low-molecular-weight heparin is preferred in the acute phase, while unfractionated heparin is reserved for patients requiring imminent neurosurgical intervention. Transition to oral anticoagulation is traditionally achieved with vitamin K antagonists, although recent randomized and observational studies suggest that direct oral anticoagulants provide similar efficacy with fewer major bleeding complications. Neurocritical care is vital for patients with severe CVT, focusing on seizure management, intracranial hypertension control, and systemic stabilization. Decompressive craniectomy is a life-saving option in cases of malignant cerebral edema. Endovascular therapy has not demonstrated superiority over standard anticoagulation and is currently reserved for refractory cases. Overall, timely diagnosis, tailored anticoagulation, and multidisciplinary critical care remain the key determinants of outcome in patients with CVT.

Downloads

Não há dados estatísticos.

Biografia do Autor

Miguel A. Vences, Servicio de Neurología, Clínica Anglo Americana. Lima, Peru. | Universidad Peruana Cayetano Heredia, Facultad de Medicina Alberto Hurtado. Lima, Peru.

     

Rodrigo Guerrero, Servicio de Neurología, Neurocirugía y Neurorradiología Intervencional, Clínica Santa María. Santiago de Chile, Chile.

     

Rodrigo Dècima, Hospital de Clínicas. Universidad de la República. Montevideo, Uruguay.

    

Julián A. Rivillas, Service de neurologie, Centre hospitalier de L'Université de Montréal. Montreal, Canada. | Université de Montréal. Montreal, Canada.

   

Referências

Zhou LW, Yu AYX, Ngo L, Hill MD, Field TS. Incidence of cerebral venous thrombosis: a population-based study, systematic review, and meta-analysis. Stroke. 2023;54(1):169-77. doi:10.1161/strokeaha.122.039390

Nguyen TN, Qureshi MM, Klein P, Yamagami H, Abdalkader M, Mikulik R, et al. Global impact of the COVID-19 pandemic on cerebral venous thrombosis and mortality. J Stroke. 2022;24(2):256-65. doi:10.5853/jos.2022.00752

Coutinho JM, van de Munckhof A, Aguiar de Sousa D, Poli S, Aaron S, Arauz A, et al. Reducing the global burden of cerebral venous thrombosis: an international research agenda. Int J Stroke. 2024;19(6):599-610. doi:10.1177/17474930241242266

Coutinho JM, Zuurbier SM, Stam J. Declining mortality in cerebral venous thrombosis: a systematic review. Stroke. 2014;45(5):1338-41. doi:10.1161/STROKEAHA.113.004666

Hiltunen S, Putaala J, Haapaniemi E, Tatlisumak T. Long-term outcome after cerebral venous thrombosis: analysis of functional and vocational outcome, residual symptoms, and adverse events in 161 patients. J Neurol. 2016;263(3):477-84. doi:10.1007/s00415-015-7996-9

Koopman K, Uyttenboogaart M, Vroomen PC, van der Meer J, De Keyser J, Luijckx GJ. Long-term sequelae after cerebral venous thrombosis in functionally independent patients. J Stroke Cerebrovasc Dis. 2009;18(3):198-202. doi:10.1016/j.jstrokecerebrovasdis.2008.10.004

Soyer B, Rusca M, Lukaszewicz AC, Crassard I, Guichard JP, Bresson D, et al. Outcome of a cohort of severe cerebral venous thrombosis in intensive care. Ann Intensive Care. 2016;6(1):29. doi:10.1186/s13613-016-0135-7

Ferro JM, Bousser MG, Canhão P, Coutinho JM, Crassard I, Dentali F, et al. European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis – endorsed by the European Academy of Neurology. Eur J Neurol. 2017;24(10):1203-13. doi:10.1111/ene.13381

Ferro JM, Aguiar de Sousa D. Cerebral venous thrombosis: an update. Curr Neurol Neurosci Rep. 2019;19(10):74. doi:10.1007/s11910-019-0988-x

Ropper AH, Klein JP. Cerebral venous thrombosis. N Engl J Med. 2021;385(1):59-64. doi:10.1056/nejmra2106545

Saposnik G, Bushnell C, Coutinho JM, Field TS, Furie KL, Galadanci N, et al. Diagnosis and management of cerebral venous thrombosis: a scientific statement from the American Heart Association. Stroke. 2024;55(3):e77-90. doi:10.1161/STR.0000000000000456

Patel H, Lunn I, Hameed S, Khan M, Siddiqui FM, Borhani A, et al. Treatment of cerebral venous thrombosis: a review. Curr Med Res Opin. 2024;40(12):2223-36. doi:10.1080/03007995.2024.2423740

Yaghi S, Shu L, Bakradze E, Omran SS, Giles JA, Amar JY, et al. Direct oral anticoagulants versus warfarin in the treatment of cerebral venous thrombosis (ACTION-CVT): a multicenter international study. Stroke. 2022;53(3):728-38. doi:10.1161/STROKEAHA.121.037541

Ferro JM, Canhão P, Stam J, Bousser MG, Barinagarrementeria F; ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004;35(3):664-70. doi:10.1161/01.str.0000117571.76197.26

Ma H, Gu Y, Bian T, Song H, Liu Z, Ji X, et al. Dabigatran etexilate versus warfarin in cerebral venous thrombosis in Chinese patients (CHOICE-CVT): an open-label, randomized controlled trial. Int J Stroke. 2024;19(6):635-44. doi: 10.1177/17474930241234749

Weimar C, Beyer-Westendorf J, Bohmann FO, Hahn G, Halimeh S, Holzhauer S, et al. New recommendations on cerebral venous and dural sinus thrombosis from the German consensus-based (S2k) guideline. Neurol Res Pract. 2024;6(1):23. doi:10.1186/s42466-024-00320-9

Ferro JM, Coutinho JM, Dentali F, Kobayashi A, Alasheev A, Canhão P, et al. Safety and efficacy of dabigatran etexilate vs dose-adjusted warfarin in patients with cerebral venous thrombosis: a randomized clinical trial. JAMA Neurol. 2019;76(12):1457-65. doi:10.1001/jamaneurol.2019.2764

Field TS, Dizonno V, Almekhlafi MA, Bala F, Alhabli I, Wong H, et al. Study of rivaroxaban for cerebral venous thrombosis: a randomized controlled feasibility trial comparing anticoagulation with rivaroxaban to standard-of-care in symptomatic cerebral venous thrombosis. Stroke. 2023;54(11):2724-36. doi:10.1161/strokeaha.123.044113

Thrombosis Canada. Cerebral venous thrombosis: clinical guide [Internet]. Thrombosis Canada; [s. f.] [citado el 24 de agosto de 2025]. Disponible en: https://thrombosiscanada.ca/hcp/practice/clinical_guides?guideID=85&language=en-ca

Rosa S, Fragata I, Aguiar de Sousa D. Update on management of cerebral venous thrombosis. Curr Opin Neurol. 2025;38(1):18-28. doi:10.1097/wco.0000000000001329

Canhão P, Ferro JM, Lindgren AG, Bousser MG, Stam J, Barinagarrementeria F; ISCVT Investigators. Causes and predictors of death in cerebral venous thrombosis. Stroke. 2005;36(8):1720-5. doi:10.1161/01.str.0000173152.84438.1c

Coutinho JM, Majoie CB, Coert BA, Stam J. Decompressive hemicraniectomy in cerebral sinus thrombosis: consecutive case series and review of the literature. Stroke. 2009;40(6):2233-5. doi:10.1161/STROKEAHA.108.543421

Théaudin M, Crassard I, Bresson D, Saliou G, Favrole P, Vahedi K, et al. Should decompressive surgery be performed in malignant cerebral venous thrombosis?: a series of 12 patients. Stroke. 2010;41(4):727-31. doi:10.1161/strokeaha.109.572909

Ferro JM, Crassard I, Coutinho JM, Canhão P, Barinagarrementeria F, Cucchiara B, et al; ISCVT 2 Investigators. Decompressive surgery in cerebrovenous thrombosis: a multicenter registry and a systematic review of individual patient data. Stroke. 2011;42(10):2825-31. doi:10.1161/STROKEAHA.111.615393

Misra S, Sudhir P, Nath M, Sharma VK, Vibha D. Decompressive surgery in cerebral venous thrombosis: a systematic review and meta-analysis. Eur J Clin Invest. 2023;53(4):e13944. doi:10.1111/eci.13944

Arauz A, Barboza MA, Quintero LC, Cantu C, Chiquete E, Serrano F. Prognosis of patients with severe cerebral venous thrombosis treated with decompressive craniectomy. Neurologia (Engl Ed). 2023;38(9):617-24. doi:10.1016/j.nrleng.2021.04.009

Greinacher A, Langer F, Makris M, Pai M, Pavord S, Tran H, et al. Vaccine-induced immune thrombotic thrombocytopenia (VITT): update on diagnosis and management considering different resources. J Thromb Haemost. 2022;20(1):149-56. doi:10.1111/jth.15572

Krzywicka K, Aguiar de Sousa D, Cordonnier C, Bode FJ, Field TS, Michalski D, et al. Decompressive surgery in cerebral venous sinus thrombosis due to vaccine-induced immune thrombotic thrombocytopenia. Eur J Neurol. 2023;30(5):1335-45. doi:10.1111/ene.15735

Aaron S, Ferreira JM, Coutinho JM, Canhão P, Conforto AB, Arauz A, et al. Outcomes of decompressive surgery for patients with severe cerebral venous thrombosis: DECOMPRESS2 observational study. Stroke. 2024;55(5):1218-26. doi:10.1161/STROKEAHA.123.045051

Bücke P, Hellstern V, Cimpoca A, Cohen JE, Horvath T, Ganslandt O, et al. Endovascular treatment of intracranial vein and venous sinus thrombosis—A systematic review. J Clin Med. 2022;11(14):4215. doi:10.3390/jcm11144215

Coutinho JM, Zuurbier SM, Bousser MG, Ji X, Canhão P, Roos YB, et al; TO-ACT investigators. Effect of endovascular treatment with medical management vs standard care on severe cerebral venous thrombosis: the TO-ACT randomized clinical trial. JAMA Neurol. 2020;77(8):966-73.doi:10.1001/jamaneurol.2020.1022

Xu Z, Li X, Feng D, Wang T, Xu X, Deng R, et al. Endovascular therapy versus anticoagulation for treatment of cerebral venous sinus thrombosis: a meta-analysis. Neurologist. 2021;27(2):69-73. doi:10.1097/nrl.0000000000000369

Siddiqui FM, Weber MW, Dandapat S, Scaife S, Buhnerkempe M, Ortega-Gutierrez S, et al. Endovascular thrombolysis or thrombectomy for cerebral venous thrombosis: study of Nationwide Inpatient Sample 2004–2014. J Stroke Cerebrovasc Dis. 2019;28(6):1440-7. doi:10.1016/j.jstrokecerebrovasdis.2019.03.025

Naik A, Smith E, Dharnipragada R, Catapano JS, Cramer SW, Johnson R, et al. Endovascular and medical management of cerebral venous thrombosis: a systematic review and network meta-analysis. World Neurosurg. 2022;165:e197-205. doi:10.1016/j.wneu.2022.05.142

Ghozy S, Orscelik A, Tolba H, Abdelghaffar M, Kobeissi H, Ghaith HS, et al. Endovascular thrombectomy for severe cerebral venous thrombosis: a comprehensive meta-analysis assessing safety and efficacy. Interv Neuroradiol. 2026;32(4):1765-74. doi:10.1177/15910199241285071

Downloads

Publicado

2026-06-30

Como Citar

1.
Vences MA, Guerrero R, Dècima R, Rivillas JA. Update on the Acute Management of Cerebral Venous Thrombosis. Rev Méd Hered [Internet]. 30º de junho de 2026 [citado 6º de novembro de 2026];37(3):248-5. Disponível em: https://revistas.upch.edu.pe/index.php/RMH/article/view/7562

Edição

Seção

REVISION DE TEMAS